Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B, Open-Label, Dose-Escalation Study of the Safety of and Antigen-specific Immune Responses Elicited by VB10.NEO in Combination With Atezolizumab in Patients With Locally Advanced and Metastatic Tumors

NCT05018273 is registered in ClinicalTrials.gov with Nykode Therapeutics ASA as lead sponsor.

NCT NCT05018273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05018273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B, Open-Label, Dose-Escalation Study of the Safety of and Antigen-specific Immune Responses Elicited by VB10.NEO in Combination With Atezolizumab in Patients With Locally Advanced and Metastatic Tumors
Lead sponsor
Nykode Therapeutics ASA
Phase
Phase 1
Overall status
Completed
Start date
December 21, 2021
Completion date
October 9, 2024
Enrollment
26 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors, adult